<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03158077</url>
  </required_header>
  <id_info>
    <org_study_id>GeSIDA 8715</org_study_id>
    <nct_id>NCT03158077</nct_id>
  </id_info>
  <brief_title>Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection</brief_title>
  <acronym>KIRAL</acronym>
  <official_title>Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection: Observational Retrospective Study at 48 Weeks - KIRAL Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion SEIMC-GESIDA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion SEIMC-GESIDA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective observational study, multicentric with Spanish hospitals, in which a switching
      or change strategy with RAL and ABC / 3TC guidelines was used, in the48 weeks before the
      start of the study, in order to determine parameters of Effectiveness and security.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a 4-weeks data recording period, during which the follow-up information
      recorded by physicians in electronic or paper medical history will be analyzed from patients
      who opted for a change to that study pattern (RAL and ABC / 3TC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2016</start_date>
  <completion_date type="Actual">April 20, 2017</completion_date>
  <primary_completion_date type="Actual">April 20, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness: Proportion of patients with undetectable viral load</measure>
    <time_frame>48 weeks</time_frame>
    <description>Effectiveness in the virological control of RAL and ABC / 3TC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety-changes in renal function: changes in creatinine values</measure>
    <time_frame>24 weeks following the change</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety-changes in renal function: changes in glomerular filtration</measure>
    <time_frame>24 weeks following the change</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Changes in serum levels of AST, ALT, FA, GGT and BIL</measure>
    <time_frame>24 weeks following the change</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Changes in serum levels of AST, ALT, FA, GGT and BIL</measure>
    <time_frame>48 weeks following the change</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Changes in serum cholesterol</measure>
    <time_frame>24 weeks following the change</time_frame>
    <description>HDL and LDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Changes in serum triglycerides</measure>
    <time_frame>24 weeks following the change</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Changes in serum cholesterol</measure>
    <time_frame>48 weeks following the change</time_frame>
    <description>HDL and LDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Changes in serum triglycerides</measure>
    <time_frame>48 weeks following the change</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse events.</measure>
    <time_frame>24 weeks/48 weeks</time_frame>
    <description>Frequency of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety:serious adverse events</measure>
    <time_frame>24 weeks/48 weeks</time_frame>
    <description>Frequency of serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: frequency of adverse events leading to discontinuation of treatment.</measure>
    <time_frame>24 weeks/48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: number of deaths</measure>
    <time_frame>24 weeks/48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: frequency of laboratory abnormalities.</measure>
    <time_frame>24 weeks/48 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">467</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir + ABC/3TC</arm_group_label>
    <description>Switching or switching strategy with RAL and ABC / 3TC guidelines, 48 weeks before the start of the study</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        HIV patients that initiated treatment with RAltegravis + ABC/3TC as a switching strategy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with chronic infection with HIV-1.

          -  Patients older than 18 years.

          -  Patients in ART in whom RAL + ABC / 3TC has been initiated in at least 48 Weeks prior
             to the start of the study.

          -  To have used the RAL + ABC / 3TC as a switching or change strategy

          -  HIV virological control (CV ≤ 50 copies / ml) for at least 24 weeks prior to
             initiation of study regimen

        Exclusion Criteria:

          -  NAIVE patients who have started treatment with this regimen

          -  Absence of digital or physical records of visits made for consultation

          -  Patients who underwent treatment change within 48 weeks prior to study initiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de Alicante</name>
      <address>
        <city>Alicante</city>
        <state>Alcante</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Mataró</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Lucia</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Severo Ochoa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de octubre</name>
      <address>
        <city>MAdrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fundación Jimenez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Prícipe de Asturias</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo hospitalario de Toledo</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Rio Hortega</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

